This study will test the safety of twice-daily oral dosing of combined febuxostat and inosine in 24 patients with Parkinson's disease. Participants will receive one of the four regimens, taken twice daily for 12 weeks:
Who can join: Adults with early-stage Parkinson's disease on stable medication regimens.
What participants do:
* Take their assigned dose twice daily (morning and evening) for 12 weeks. * Visit the clinic at baseline and weeks 4, 8, and 12 for blood tests (including hypoxanthine), exams, and questionnaires. * Keep a simple diary of any side effects or changes in daily activities.
Risks and benefits: Possible side effects include mild gastrointestinal upset, headache, or elevated uric acid levels. While direct benefit is not guaranteed, this safety data will inform future Parkinson's disease treatments.
Learn more: Contact \[site-specific contact info\] for details on eligibility and enrollment.
Able to provide voluntary written informed consent.
Receiving stable Parkinson's disease medication (no changes in type or dose) for at least 3 months before enrollment.
Age 18 to 80 years at the time of consent.
Hoehn-Yahr stage (ON state) 1 to 3
Requires almost total assistance in daily life and is unable to walk or stand unaided.
Currently taking azathioprine, mercaptopurine hydrate, vidarabine, didanosine, or rosuvastatin.
Used febuxostat, allopurinol, or topiroxostat within 3 months before study start.
Taking any supplement containing inosine.